- Atara Biotherapeutics (NASDAQ:ATRA) intends to present 15-month safety and efficacy data from all patients in the two highest dose cohorts of the Phase 1a study of ATA188 at European Charcot Foundation meeting Nov 15-19 following patient responses that "likely indicate a treatment effect with ATA188,” said Jakob Dupont, Global Head, Research and Development at Atara.
- Following the results, ATRA noted that it is to boost the size to at least 64 patients, while adjusting the primary endpoint of the study. The endpoint will be changed to disability improvement, and maintaining biological and functional endpoints.
- https://seekingalpha.com/news/3636398-atara-biotherapeutics-to-boost-ata188-investment-in-multiple-sclerosis-treatment
Sunday, November 15, 2020
Atara Biotherapeutics to boost ATA188 investment in MS treatment
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.